Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways
Sara Muhammad El-Hanboshy, Maged W. Helmy, Mohammad M. Abd‐Alhaseeb
Topics & Concepts
PI3K/AKT/mTOR pathwayRegorafenibProtein kinase BHepatocellular carcinomaCancer researchVEGF receptorsChemistrySignal transductionPharmacologyMedicineInternal medicineColorectal cancerCancerBiochemistryPhytochemistry and Biological ActivitiesFlavonoids in Medical ResearchBioactive Compounds in Plants